Reveal the potential molecular mechanism of circRNA regulating immune-related mRNA through sponge miRNA in the occurrence and immune regulation of papillary thyroid cancer

References

• Wang J, Zhanghuang C, Jin L, et al. Development and validation of a nomogram to predict cancer-specific survival in elderly patients with papillary thyroid carcinoma: a population-based study. BMC Geriatr. 2022;22(1):1. doi: 10.1186/s12877-022-03430-8.
   PubMed Web of Science ®Google Scholar
• Lam AK. Papillary thyroid carcinoma: current position in epidemiology, genomics, and classification. Meth Molr Biol. 2022;2534:1–17.
   PubMedGoogle Scholar
• Wu Z, Han L, Li W, et al. Which is preferred for initial treatment of papillary thyroid cancer, total thyroidectomy or lobotomy? Cancer Med. 2021;10(5):1614–1622. doi: 10.1002/cam4.3743.
   PubMed Web of Science ®Google Scholar
• Dong W, Horiuchi K, Tokumitsu H, et al. Time-varying pattern of mortality and recurrence from papillary thyroid cancer: lessons from a long-term follow-up. Thyroid. 2019;29(6):802–808. doi: 10.1089/thy.2018.0128.
   PubMed Web of Science ®Google Scholar
• Chen L, Wang C, Sun H, et al. The bioinformatics toolbox for circRNA discovery and analysis. Brief Bioinform. 2021;22(2):1706–1728. doi: 10.1093/bib/bbaa001.
   PubMed Web of Science ®Google Scholar
• Zang J, Lu D, Xu A. The interaction of circRNAs and RNA binding proteins: an important part of circRNA maintenance and function. J Neurosci Res. 2020;98(1):87–97. doi: 10.1002/jnr.24356.
   PubMed Web of Science ®Google Scholar
• Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, et al. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–5465. doi: 10.1002/jcp.27486.
   PubMed Web of Science ®Google Scholar
• Zhu G, Chang X, Kang Y, et al. CircRNA: a novel potential strategy to treat thyroid cancer . Int J Mol Med. 2021;48(5):201. doi: 10.3892/ijmm.2021.5034.
   Web of Science ®Google Scholar
• Li C, Zhu L, Fu L, et al. CircRNA NRIP1 promotes papillary thyroid carcinoma progression by sponging mir-195-5p and modulating the P38 MAPK and JAK/STAT pathways. Diagn Pathol. 2021;16(1):93. doi: 10.1186/s13000-021-01153-9.
   PubMed Web of Science ®Google Scholar
• Yao Y, Chen X, Yang H, et al. Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis. J Exp Clin Cancer Res. 2019;38(1):318.
   Google Scholar
• Wang M, Chen B, Ru Z, et al. CircRNA circ-ITCH suppresses papillary thyroid cancer progression through miR-22-3p/CBL/β-catenin pathway. Biochem Biophys Res Commun. 2018;504(1):283–288. doi: 10.1016/j.bbrc.2018.08.175.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Na KJ, Choi H. Immune landscape of papillary thyroid cancer and immunotherapeutic implications. Endocr Relat Cancer. 2018;25(5):523–531. doi: 10.1530/ERC-17-0532.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang C, Zhu Y, et al. TREM1 fosters an immunosuppressive tumor microenvironment in papillary thyroid cancer. Endocr Relat Cancer. 2022;29(2):71–86. doi: 10.1530/ERC-21-0297.
   PubMed Web of Science ®Google Scholar
• Jin A, Zhou J, Yu P, et al. High expression of THBS1 leads to a poor prognosis in papillary thyroid cancer and suppresses the anti-tumor immune microenvironment. Technol Cancer Res Treat. 2022;21:15330338221085360. doi: 10.1177/15330338221085360.
   Web of Science ®Google Scholar
• Wu Z, Liu P, Zhang G. Identification of circRNA-miRNA-immune-related mRNA regulatory network in gastric cancer. Front Oncol. 2022;12:816884. doi: 10.3389/fonc.2022.816884.
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally Portraying the Tissue Cellular Heterogeneity Landscape. Genome Biol. 2017;18(1):220.
   Google Scholar
• Šimundić AM. Measures of diagnostic accuracy: basic definitions. Ejifcc. 2009;19(4):203–211.
   PubMedGoogle Scholar
• Vasileiadis I, Boutzios G, Karalaki M, et al. Papillary thyroid carcinoma of the isthmus: total thyroidectomy or isthmusectomy? Am J Surg. 2018;216(1):135–139. doi: 10.1016/j.amjsurg.2017.09.008.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu J, Yang T, et al. Circ_0082182 upregulates the NFIB level via sponging miR-326 to promote oxaliplatin resistance and malignant progression of colorectal cancer cells2022.
   Google Scholar
• Liu R, Deng P, Zhang Y, et al. Circ_0082182 promotes oncogenesis and metastasis of colorectal cancer in vitro and in vivo by sponging miR-411 and miR-1205 to activate the wnt/β-catenin pathway. World J Surg Oncol. 2021;19(1):51. doi: 10.1186/s12957-021-02164-y.
   PubMed Web of Science ®Google Scholar
• Gao T, Zhao L, Zhang F, et al. Evaluate the diagnostic and prognostic value of NUSAP1 in papillary thyroid carcinoma and identify the relationship with genes, proteins, and immune factors. World J Surg Oncol. 2022;20(1):207. doi: 10.1186/s12957-022-02652-9.
   PubMed Web of Science ®Google Scholar
• He J, Yu L, Wang CM, et al. MiR-1275 promotes non-small cell lung cancer cell proliferation and metastasis by regulating LZTS3 expression. Eur Rev Med Pharmacol Sci. 2022;26(7):2215.
   PubMed Web of Science ®Google Scholar
• Eggo MC, Hopkins JM, Franklyn JA, et al. Expression of fibroblast growth factors in thyroid cancer. J Clin Endocrinol Metab. 1995;80(3):1006–1011. doi: 10.1210/jcem.80.3.7533768.
   PubMed Web of Science ®Google Scholar
• Guan H, Guo Y, Liu L, et al. INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression. Cell Biosci. 2018;8:26. doi: 10.1186/s13578-018-0224-4.
   PubMed Web of Science ®Google Scholar
• Kim EK, Song MJ, Jang HH. Clinicopathologic analysis of cathepsin B as a prognostic marker of thyroid cancer. Int J Mol Sci. 2020;21(24):9537.
   Google Scholar
• Jarzab B, Wiench M, Fujarewicz K, et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 2005;65(4):1587–1597. doi: 10.1158/0008-5472.CAN-04-3078.
   PubMed Web of Science ®Google Scholar
• Bruland O, Fluge Ø, Akslen LA, et al. Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas. BMC Cancer. 2009;9:425. doi: 10.1186/1471-2407-9-425.
   PubMed Web of Science ®Google Scholar
• Chen Q, Liu T, Bao Y, et al. CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway. Cancer Lett. 2020;469:68–77. doi: 10.1016/j.canlet.2019.10.017.
   PubMed Web of Science ®Google Scholar
• Ni T, Li Y, Guo D, et al. LncRNA DNAJC3-AS1 promotes the biological functions of papillary thyroid carcinoma via regulating the microRNA-27a-3p/CCBE1 axis. Cell Biol Int. 2023;47(3):539–547. doi: 10.1002/cbin.11946.
   PubMed Web of Science ®Google Scholar
• Pan YQ, Huang KS, Chong TH, et al. LINC01089 blocks malignant progression of thyroid cancer by binding miR-27b-3p to enhance the FBLN5 protein level. Discov Oncol. 2022;13(1):114. doi: 10.1007/s12672-022-00580-4.
   PubMedGoogle Scholar
• Luo Y, Chen R, Ning Z, et al. Identification of a four-gene signature for determining the prognosis of papillary thyroid carcinoma by integrated bioinformatics analysis. Int J Gen Med. 2022;15:1147–1160. doi: 10.2147/IJGM.S346058.
   PubMed Web of Science ®Google Scholar
• Yuan J, Liu Z, Liu J, et al. Circ_0060055 promotes the growth, invasion, and radioresistance of glioblastoma by targeting MiR-197-3p/API5 axis. Neurotox Res. 2022;40(5):1292–1303. doi: 10.1007/s12640-022-00548-w.
   PubMed Web of Science ®Google Scholar
• Sun R, Li H, Li J, et al. CircRNA circ-0038718 promotes hepatocellular carcinoma progression through sponging miR-139-3p. Biochem Biophys Res Commun. 2020;533(4):845–852. doi: 10.1016/j.bbrc.2020.07.035.
   PubMed Web of Science ®Google Scholar
• Gu H, Xu Z, Zhang J, et al. Circ_0038718 promotes colon cancer cell malignant progression via the miR-195-5p/Axin2 signaling axis and also effect wnt/β-catenin signal pathway. BMC Genomics. 2021;22(1):768. doi: 10.1186/s12864-021-07880-z.
   PubMed Web of Science ®Google Scholar
• Koshizuka K, Hanazawa T, Kikkawa N, et al. Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma. Auris Nasus Larynx. 2018;45(4):854–865. doi: 10.1016/j.anl.2017.11.019.
   PubMed Web of Science ®Google Scholar
• Oler G, Camacho CP, Hojaij FC, et al. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res. 2008;14(15):4735–4742. doi: 10.1158/1078-0432.CCR-07-4372.
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Chindris AM, Asmann YW, et al. RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014;99(2):E338–47. doi: 10.1210/jc.2013-2792.
   PubMed Web of Science ®Google Scholar
• Chunyan Z, Yanpeng H, Changshun X, et al. Potential value of circular RNA circTBC1D4 in gastrointestinal stromal tumors. J Immunol Res. 2022;2022:9019097.
   Google Scholar
• Guo Y, Zheng H, Yin J, et al. Rs4911154 of circ-ITCH aggravated tumor malignancy of thyroid nodules via the circ-ITCH/miR-22-3p/CBL axis. Sci Rep. 2021;11(1):18491. doi: 10.1038/s41598-021-97471-5.
   PubMed Web of Science ®Google Scholar
• Dettmer MS, Perren A, Moch H, et al. MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. J Mol Endocrinol. 2014;52(2):181–189. doi: 10.1530/JME-13-0266.
   PubMed Web of Science ®Google Scholar
• Huang P, Mao LF, Zhang ZP, et al. Down-regulated miR-125a-5p promotes the reprogramming of glucose metabolism and cell malignancy by increasing levels of CD147 in thyroid cancer. Thyroid. 2018;28(5):613–623. doi: 10.1089/thy.2017.0401.
   PubMed Web of Science ®Google Scholar
• Franzén A, Heldin NE. BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun. 2001;285(3):773–81. doi: 10.1006/bbrc.2001.5212.
   PubMed Web of Science ®Google Scholar
• Li CW, Shi X, Ma B, et al. A 4 gene-based immune signature predicts dedifferentiation and immune exhaustion in thyroid cancer. J Clin Endocrinol Metab. 2021;106(8):e3208–e20. doi: 10.1210/clinem/dgab132.
   PubMed Web of Science ®Google Scholar
• Guan E, Liu H, Xu N. Lidocaine suppresses gastric cancer development through circ_ANO5/miR-21-5p/LIFR axis. Dig Dis Sci. 2022;67(6):2244–2256. doi: 10.1007/s10620-021-07055-6.
   PubMed Web of Science ®Google Scholar
• Wu HX, Cheng X, Jing XQ, et al. LIFR promotes tumor angiogenesis by up-regulating IL-8 levels in colorectal cancer. Biochim Biophys Acta Mol Basis Dis. 2018;1864(9 Pt B):2769–2784. doi: 10.1016/j.bbadis.2018.05.004.
   PubMed Web of Science ®Google Scholar
• Spangler JB, Moraga I, Mendoza JL, et al. Insights into cytokine-receptor interactions from cytokine engineering. Annu Rev Immunol. 2015;33:139–167. doi: 10.1146/annurev-immunol-032713-120211.
   PubMed Web of Science ®Google Scholar
• Wang T, Shi J, Li L, et al. Single-cell transcriptome analysis reveals inter-tumor heterogeneity in bilateral papillary thyroid carcinoma. Front Immunol. 2022;13:840811. doi: 10.3389/fimmu.2022.840811.
   PubMed Web of Science ®Google Scholar
• Zhao N, Liu X, Wu C, et al. Changes in treg numbers and activity in papillary thyroid carcinoma with and without Hashimoto’s thyroiditis. J Int Med Res. 2020;48(4):300060520919222. doi: 10.1177/0300060520919222.
   PubMed Web of Science ®Google Scholar
• Haas S, Trumpp A, Milsom MD. Causes and consequences of hematopoietic stem cell heterogeneity. Cell Stem Cell. 2018;22(5):627–638. doi: 10.1016/j.stem.2018.04.003.
   PubMed Web of Science ®Google Scholar
• Gaide Chevronnay HP, Janssens V, Van Der Smissen P, et al. Hematopoietic stem cells transplantation can normalize thyroid function in a cystinosis mouse model. Endocrinology. 2016;157(4):1363–1371. doi: 10.1210/en.2015-1762.
   PubMed Web of Science ®Google Scholar
• Lee TY, Lee S, Bae JS, et al. Distinct clinical manifestations of thyroid cancer after hematopoietic stem cell transplantation. Ann Surg Oncol. 2019;26(11):3586–3592. doi: 10.1245/s10434-019-07442-4.
   PubMed Web of Science ®Google Scholar
• Hilly O, Rath-Wolfson L, Koren R, et al. CD1a-positive dendritic cell density predicts disease-free survival in papillary thyroid carcinoma. Pathol Res Pract. 2015;211(9):652–656. doi: 10.1016/j.prp.2015.05.009.
   PubMed Web of Science ®Google Scholar
• Song L, Zhu J, Li Z, et al. The prognostic value of the lymphocyte-to-monocyte ratio for high-risk papillary thyroid carcinoma. Cancer Manag Res. 2019;11:8451–8462. doi: 10.2147/CMAR.S219163.
   PubMed Web of Science ®Google Scholar
• Yokota M, Katoh H, Nishimiya H, et al. Lymphocyte-monocyte ratio significantly predicts recurrence in papillary thyroid cancer. J Surg Res. 2020;246:535–543. doi: 10.1016/j.jss.2019.09.034.
   PubMed Web of Science ®Google Scholar